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Abstract
Background: Nicorandil, an anti-angina agent, reportedly improves outcomes even in angina patients with
diabetes. However, the precise mechanism underlying the beneficial effect of nicorandil on diabetic patients has
not been examined. We investigated the protective effect of nicorandil on endothelial function in diabetic rats
because endothelial dysfunction is a major risk factor for cardiovascular disease in diabetes.
Methods: Male Sprague-Dawley rats (6 weeks old) were intraperitoneally injected with streptozotocin (STZ, 40 mg/
kg, once a day for 3 days) to induce diabetes. Nicorandil (15 mg/kg/day) and tempol (20 mg/kg/day, superoxide
dismutase mimetic) were administered in drinking water for one week, starting 3 weeks after STZ injection.
Endothelial function was evaluated by measuring flow-mediated dilation (FMD) in the femoral arteries of
anaesthetised rats. Cultured human coronary artery endothelial cells (HCAECs) were treated with high glucose (35.6
mM, 24 h) and reactive oxygen species (ROS) production with or without L-NAME (300 μM), apocynin (100 μM) or
nicorandil (100 μM) was measured using fluorescent probes.
Results: Endothelial function as evaluated by FMD was significantly reduced in diabetic as compared with
normal rats (diabetes, 9.7 ± 1.4%; normal, 19.5 ± 1.7%; n = 6-7). There was a 2.4-fold increase in p47
phox
expression, a subunit of NADPH oxidase, and a 1.8-fold increase in total eNOS expression in diabetic rat femoral
arteries. Nicorandil and tempol significantly improved FMD in diabetic rats (nicorandil, 17.7 ± 2.6%; tempol, 13.3
± 1.4%; n = 6). Nicorandil significantly inhibited the increased expressions of p47
phox and total eNOS in diabetic
rat femoral arteries. Furthermore, nicorandil significantly inhibited the decreased expression of GTP
cyclohydrolase I and the decreased dimer/monomer ratio of eNOS. ROS production in HCAECs was increased by
high-glucose treatment, which was prevented by L-NAME and nicorandil suggesting that eNOS itself might
serve as a superoxide source under high-glucose conditions and that nicorandil might prevent ROS production
from eNOS.
Conclusions: These results suggest that nicorandil improved diabetes-induced endothelial dysfunction through
antioxidative effects by inhibiting NADPH oxidase and eNOS uncoupling.
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Diabetes mellitus is regarded as an independent major
risk factor for the development of cardiovascular disease,
since long-term survival and freedom from cardiac
events were reduced in diabetic coronary angioplasty
patients [1-3]. Endothelial dysfunction plays a central
role in diabetic vascular diseases [4]. A common
mechanism underlying this endothelial dysfunction
could involve increased production of reactive oxygen
species (ROS) in vascular tissue [5]. High glucose greatly
increases endothelial superoxide production [6], leading
to an eNOS uncoupling state, followed by reduction of
NO production and increased ROS production [7-11]
which act to quench NO. Reduced NO availability will
lead to attenuation of its beneficial vascular effects such
as vasodilation, regulation of vascular smooth muscle
proliferation, and expression of cellular adhesion mole-
cules involved in the initiation of atherosclerotic plaque
formation [12]. Therefore, increased ROS production in
diabetes has been speculated to reduce endothelial NO
availability, leading to endothelial dysfunction [13,14].
Nicorandil, an anti-angina agent with ATP-sensitive
potassium channel opening and nitrate-like activity, report-
edly improves prognosis in patients with angina pectoris via
preconditioning effects [15], and also exerted endothelial
protective effects in both clinical settings and animal stu-
dies. Long-term administration of nicorandil significantly
improved endothelial function in patients with ischemic
heart disease or with cardiovascular risk factors, as evalu-
ated by measurement of flow-mediated dilation (FMD) in
forearm arteries [16,17]. In the swine heart, nicorandil
reduced myocardial no-reflow after ischemia reperfusion by
protecting endothelial function [18]. In human umbilical
vein endothelial cells, nicorandil inhibited apoptosis
induced by serum starvation by inhibiting ROS production
[19]. Furthermore, nicorandil protected from diabetic
through inhibition of the production of ROS stimulated by
high glucose [20]. Therefore, we hypothesised that nicoran-
dil can prevent diabetic endothelial dysfunction.
In the present study, we investigated the protective
effect of nicorandil on endothelial function in streptozo-
tocin (STZ)-induced diabetic rats by measuring FMD in
femoral arteries using a high-resolution ultrasound sys-
tem under in vivo conditions in which blood flow, many
humoral factors and nerve activity were maintained. The
mechanism underlying the protective action of nicoran-
dil was also investigated in relation to ROS production
in the endothelium both in vivo and in vitro.
Methods
Animals
Male Sprague-Dawley rats (Charles River Japan, Yoko-
hama, Japan, 6 weeks old, 200-240 g) were used in all
experiments. All rats were fed ordinary laboratory chow
and allowed free access to water under a constant light
and dark cycle of 12 h. Diabetes was induced by intra-
peritoneal administration of STZ (40 mg/kg) once a day
for 3 days. One week after STZ administration, glucose
concentrations were measured. Diabetes was considered
to have been induced when the glucose level was higher
than 250 mg/dL. Nicorandil (15 mg/kg/day) and tempol
(20 mg/kg/day) were administered in drinking water for
one week, starting 3 weeks after STZ administration.
All animal procedures were conducted in accordance
with Chugai Pharmaceutical’s ethical guidelines for ani-
mal care, and all experimental protocols were approved
by the Animal Care Committee of the institution and
c o n f o r m e dt ot h eG u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals published by the US National insti-
tutes of Health.
Measurement of FMD
Four weeks after STZ administration, blood pressure
(tail-cuff method, BP-98A Softron, Tokyo, Japan) and
blood glucose were measured, and the rats were anaes-
thetised with thiobutabarbital with constant monitoring
of rectal temperature. The animals were kept stable with
a heated sheet and warming lamps directed at each rat.
Femoral arterial diameter and Doppler flow were mea-
sured using a high-resolution ultrasound system (Vevo
770, VisualSonics, Toronto, Canada). The femoral artery
was visualised with a 30- or 40-MHz transducer. After
identification of the femoral artery by its characteristic
flow pattern, the probe position was optimised to show
clear vessel wall/lumen interfaces and fixed throughout
the investigations. Experiments were started over a 15-
min equilibration period and when body core tempera-
ture (37 ± 1°C) was stable.
FMD measurement in rats was described previously
[21]. Ultrasound diameter and Doppler-flow measure-
ments were obtained from longitudinal sections of the
femoral artery before and after 5 min of hindlimb ische-
mia. Ischemia and reperfusion of the hindlimb were
achieved with a snare occluder positioned upstream
from the site to be visualised, around the common iliac
artery, through a trans-abdominal access. The snare
occluder consisted of a 5-0 nylon surgical suture around
t h ea r t e r ya n dp a s s e dt h r o u g ha4c mP E - 2 0 0t u b e ,a n d
the skin was closed with surgical clips. Hindlimb ische-
mia was achieved by pulling on the filament through the
tube and clamping with a clamp.
After an equilibration period, baseline recordings were
taken and the common iliac artery was occluded with
the snare occluder. Flow arrest was confirmed by abro-
gation of the Doppler signal. After 5 min of ischemia,
the hindlimb was reperfused by release of the occluder.
The changes in flow velocity and the diameter of the
femoral artery were monitored at 0, 0.5, 1, 2 and 3 min
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peak changes of femoral artery diameter measured at 1
min after reperfusion, since clinical guideline for FMD
assessment defined the peak changes of brachial artery
diameter as an endothelial function, which is occurred
about 1 min after reperfusion [22].
For evaluation of endothelium-independent vasodila-
tion, nitroglycerin (NTG) was administered after FMD
measurement to the same rats with 10 min breaks
between measurements. After obtaining baseline record-
ings for diameter, NTG (5 μg/kg) was intravenously
administered via a jugular vein catheter. Changes in
femoral artery in the diameters were monitored at 10,
30, 60 and 120 sec after administration.
Western blot analysis
Femoral arteries were harvested and frozen in liquid N2
immediately after isolation and stored in a -80°C in a
freezer until measurement of protein by Western blot-
ting. The femoral artery was homogenised in homogeni-
sation buffer, composed of 25 mM Tris-HCl (pH 7.4), 1
mM dithiolthreitol, 25 mM sodium fluoride, 1 mM
sodium orthovanadate, protease inhibitor cocktail tablet,
phosphatase inhibitor cocktail and 1% Triton X-100.
The homogenates were centrifuged at 14,000 g for 20
min at 4°C. Supernatants were collected, and protein
concentrations were determined using a BCA Protein
Assay Kit (Thermo Scientific, Woltham, USA). Equal
amounts of protein extracts were separated on 10%
SDS-polyacrylamide gel and immobilised on polyvinyli-
dene difluoride (PVDF) membranes (Millipore, Billerica,
USA). The membranes were blocked in PVDF Blocking
Reagent (TOYOBO, Osaka, Japan), and incubated with
anti-p47
phox antibodies, anti-eNOS antibodies (Santa
Cruz Biotechnology, Santa Cruz, USA) or anti-GTP
cyclohydrolase I (GCH-I) antibodies (Abnova, Taipei,
Taiwan). After washing, the membranes were incubated
with anti-rabbit or anti-goat IgG conjugated with horse-
radish peroxidise (Santa Cruz Biotechnology). Immunor-
eactive signals were visualised with SuperSignal West
Dura Extended Duration Substrate (Thermo Scientific),
and detected using a ChemiDoc XRS system (Bio-Rad
Laboratories, Hercules, USA). Each protein signal was
normalised to b-actin expression from the same sample.
Measurement of serum NOx
For the measurement of NO excretion, the total nitrate
and nitrite (NOx) concentrations were measured by the
Griess method with a Total Nitric Oxide Assay Kit
(Enzo Life Sciences, Farmingdale, USA). Serum samples
were diluted 1:2 into reaction buffer and ultra-filtered
through a 10,000 molecular weight cut-off filter. Sam-
ples were read at 540 nm with a Microplate Reader
(Molecular Devices, Sunnyvale, USA).
Cell culture and treatment
Normal human coronary artery endothelial cells
(HCAECs) were purchased from Lonza (Walkersville, MD,
USA). HCAECs at passages 3-5 were cultured with EBM-2
supplemented with 5% fetal bovine serum (Lonza). For the
measurement of ROS production, the cells were seeded
onto plastic dishes (1 × 10
5 cells/2 mL/dish) and cultured
as monolayers in a 5% CO2 humidified incubator at 37°C.
After overnight incubation, HCAECs were exposed to nor-
mal glucose (5.6 mM) or high glucose (35.6 mM) for 24 h.
Nicorandil (100 μM), apocynin (100 μM, Calbiochem,
Darmstadt, Germany) or L-NAME (300 μM, St Louis,
Sigma-Aldrich) was added over the same period.
Measurement of ROS production using the fluorescent
probe in HCAECs
The ROS production level was monitored using the
fluorescent probe 2’,7 ’-dichlorodihydrofluorescein dia-
cetate (H2DCF-DA) (Invitrogen, Carlsbad, USA). Briefly,
cultured cells were incubated with 10 μMH 2DCF-DA
for 45 min in a 37°C incubator, and 2’,7 ’-dichlorofluor-
escein (DCF) fluorescence was then quantified employ-
ing confocal microscopy (Zeiss Axiovert 200) from at
least 20 randomly-selected cells/dish, using three dishes
for each experimental condition.
Statistical analyses
All data are expressed as mean ± SE. The n values refer to
the number of individual animals on which experiments
were performed. The statistical significance of differences
was determined using Tukey’s Multiple Comparison Test.
Probability values less than 0.05 were considered signifi-
cant. Statistical analyses were performed using SAS ver-
sion 8.2 software (SAS Institute, Cary, USA).
Results
Animals
Body weight, blood glucose, blood pressure and heart
rate are shown in Table 1. For 4 weeks after STZ
Table 1 Body weight, blood glucose, blood pressure and
heart rate at 4 weeks after STZ administration
normal STZ STZ
+nicorandil
N7 6 6
Body weight (g) 417.8 ± 8.7 299.4 ±
15.4*
327.7 ± 9.8*
Blood glucose (mg/dL) 96.7 ± 1.7 392.3 ±
17.4*
424.5 ± 16.1*
Systolic blood pressure
(mmHg)
121.8 ± 1.8 135.4 ± 5.9 133.5 ± 3.2
Heart rate (bpm) 359.4 ±
11.9
312.4 ±
14.5*
334.5 ± 11.4
*p < 0.05 vs normal
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rats, although the increase in the STZ rats was smaller
than that in normal rats. Blood glucose levels in STZ
rats were significantly higher than those in normal rats.
Systolic blood pressure was slightly increased while
heart rate was significantly decreased in STZ rats.
Nicorandil influenced none of these parameters.
FMD in STZ-induced diabetic rats
Endothelial function was evaluated by the measurement
of FMD in rat femoral arteries. Reperfusion after 5-min
hindlimb ischemia instantaneously increased flow velo-
city (i.e. reactive hyperaemia) compared with baseline
femoral artery flow, followed by a rapid decay to base-
line values at around 3 min (Figure 1A). The increase in
flow velocity was associated with a delayed increase in
femoral arterial vasodilation that peaked at 1 min after
reperfusion (Figure 1B). This delayed vasodilation in the
femoral artery was observed as FMD. In the evaluation
of endothelium-independent vasodilatory potency,
intravenous administration of NTG led to vasodilation
of the femoral artery that peaked at 30 sec (Figure 1C).
In diabetic rats, peak velocity in the femoral artery was
lower than that in normal rats (normal, 106.7 ± 5.0;
STZ, 49.5 ± 2.5 mm/s; n = 6-7, Figure 1A) at baseline (i.
e. before ischemia). However, hyperaemia, expressed as
the % change in peak velocity just after reperfusion, did
not differ between normal and STZ rats (Figure 1D).
FMD was decreased in STZ rats compared with normal
rats (normal, 19.5 ± 1.7; STZ, 9.7 ± 1.4%; n =6 - 7 ,F i g -
ure 1B, E). NTG-induced vasodilation was similar in
normal and STZ rats (Figure 1C, F).
For the evaluation of nicorandil effects on endothelial
function in STZ rats, nicorandil (15 mg/kg/day) was
administered in drinking water for one week starting 3
weeks after STZ administration. Nicorandil restored the
reduced FMD in STZ rats to almost same level as in
normal rats (STZ + Nicorandil, 17.7 ± 2.6%; n =6 ,F i g -
ure 1B, E), whereas nicorandil affected neither NTG-
induced vasodilation nor flow velocity. In normal rats,
Figure 1 Effect of nicorandil on STZ-induced endothelial dysfunction in rats. Ultrasound measurements were performed at 4 weeks after
STZ administration. Time courses of velocity (A), FMD (B) and NTG-induced vasodilation (C) in rat femoral arteries were measured after 5-min
ischemia. Δ% of velocity (D) and NTG-induced vasodilation (F) were similar among groups. FMD peaked at 1 min after reperfusion and then
decreased in diabetic rats, showing improvement by nicorandil (E). *p < 0.05 vs normal, #p < 0.05 vs STZ (n = 6-7).
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mal, 18.8 ± 4.0; nicorandil, 20.9 ± 1.7%; n =5 - 6 ) .T h e s e
results demonstrated nicorandil ameliorate endothelial
dysfunction, without changing flow velocity or vascular
smooth muscle function, in STZ rats.
Involvement of oxidative stress in decreased FMD in STZ-
induced diabetic rats
To clarify the involvement of oxidative stress in the
endothelial dysfunction in STZ rats, the effect of tempol
was investigated. Tempol significantly reversed the FMD
decrease in STZ rats (STZ, 6.5 ± 1.5; STZ + Tempol,
13.3 ± 1.4%; n = 6, Figure 2). Because NADPH oxidase
is known to be a potential source of vascular superoxide
production, we measured its expression in STZ rat
femoral arteries. In STZ rats, p47
phox protein, which is
major NADPH oxidase component, was increased in the
femoral artery (Figure 3A). To examine whether
endothelial dysfunction is associated with reduced eNOS
expression, we measured total eNOS expression in the
rat femoral artery. Total eNOS expression was increased
in STZ rat femoral arteries (Figure 3B). However, this
increase in total eNOS expression did not raise serum
NOx levels in STZ rats and nicorandil also showed no
significant changes (normal, 9.3 ± 0.6; STZ, 11.3 ± 1.8;
STZ + nicorandil, 13.2 ± 3.0 μM, n = 6-8). In oxidative
state, reduction in tetrahydrobiopterin (BH4)r e s u l t si n
uncoupling of eNOS, resulting in production of super-
oxide by eNOS monomer [8]. In this study, eNOS
dimer/monomer ratio was decreased (Figure 3C), and
GCH-I expression, a synthetase of BH4, was also
decreased in STZ rat femoral arteries (Figure 3D).
Nicorandil restored p47
phox, GCH-1 and total eNOS
expressions and also eNOS dimer/monomer ratio in
STZ rat femoral artery to normal values (Figure 3).
High glucose-induced ROS production in HCAECs
To clarify the possibility that eNOS itself might serve as
a source of superoxide in the diabetic state, we exam-
ined the influence of the NOS inhibitor L-NAME on
high glucose-induced ROS production in HCAECs.
High glucose increased DCF fluorescence in HCAECs.
Interestingly, L-NAME decreased high glucose-induced
ROS production in HCAECs (Figure 4A-D), indicating
Figure 2 Effect of tempol on STZ-induced endothelial
dysfunction in rats. Ultrasound measurements were performed at
4 weeks after STZ administration. Data indicate the % changes of
femoral diameter at 1 min after reperfusion. Tempol improved the
FMD decrease in diabetic rats. #p < 0.05 vs STZ (n = 6).
Figure 3 Effects of nicorandil on p47
phox and total eNOS, GCH-
1 expressions and eNOS uncoupling in rat femoral artery.
Nicorandil normalised increased p47
phox protein (A) and total eNOS
protein (B) in diabetic rat femoral arteries. Nicorandil also
normalized decreased eNOS dimer/monomer ratio (C) and GCH-1
protein (D) in diabetic rat femoral arteries. Femoral arteries were
harvested 4 weeks after STZ administration. *p < 0.05 vs normal, #p
< 0.05 vs STZ (n = 6-8).
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Furthermore, apocynin, an NADPH oxidase inhibitor,
also decreased high glucose-induced ROS production in
HCAECs (Figure 4E-H). Nicorandil also prevented high
glucose-induced ROS production in HCAECs (Figure
5A-D).
Discussion
The present study demonstrated that nicorandil pro-
tected from the endothelial dysfunction assessed by the
FMD reduction without affecting endothelium-indepen-
dent vasodilation in STZ rats. Since earlier report has
shown that diabetes-induced endothelial dysfunction
was caused by increased ROS [5], there would be 2 pos-
sibilities as the underlying mechanisms of endothelial
protective effect; Nicorandil could inhibit both the
expression and activity of NADPH oxidase, a major
source of ROS [23,24], leading to the reduction of ROS
production. Secondly, since monomer state of eNOS is a
source of ROS but not NO depending on the BH4 level
[8], nicorandil could inhibit the monomerization of
eNOS by increased expression of BH4 synthase in
arteries of STZ rats, resulting in the reduction of ROS
production. The present results suggested that nicoran-
dil may offer a novel strategy for diabetes complication
therapy targeting endothelial dysfunction due to ROS
production.
Endothelial dysfunction and NADPH oxidase in diabetes
Endothelial dysfunction is attributable to endothelial
ROS production derived from vascular NADPH oxidase,
an important vascular source of superoxide [23,24]. Pre-
sent results are with general agreement with earlier
reports that endothelial dependent relaxation of artery
was impaired by the increased ROS production via
NADPH oxidase in both type I [25,26] and type II dia-
betic model [27,28]. The present study demonstrated
that tempol, a radical scavenger improved the reduced
FMD (Figure 2), and that the expression of NADPH oxi-
dase subunit p47
phox was increased in femoral artery
(Figure 3A) as well as apocynin significantly decreased
high glucose-induced ROS production in HCAECs (Fig-
ure 4H), indicating that the endothelial dysfunction in
STZ rats was caused by the increased oxidative stress
produced by NADPH oxidase. Moreover, nicorandil
inhibited expression of NADPH oxidase in STZ rat
Figure 4 Effect of L-NAME and apocynin on ROS production induced by high-glucose treatment in HCAECs. HCAECs were exposed to
high glucose (35.6 mM) for 24 h, and L-NAME (300 μM) or apocynin (100 μM) for the same period. Representative images show DCF
fluorescence in control (A, E), high-glucose treatment (B, F) and high-glucose + L-NAME (C) or + apocynin (G). High-glucose treatment increased
ROS production, which was prevented by L-NAME (D) or apocynin (H). *p < 0.05 vs control, #p < 0.05 vs high-glucose (20 cells/dish from 2-3
dishes). Scale bar = 100 μm.
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glucose-induced ROS production in HCAECs (Figure 5).
These results suggest that nicorandil ameliorates
endothelial dysfunction by inhibiting ROS production
through decreased NADPH oxidase expression in STZ
rats. This is in general agreement with a previous report
showing that nicorandil can inhibit ROS production
through NADPH oxidase activation in response to
hypoxia-reoxygenation in human umbilical vein
endothelial cells [29].
The increased NADPH oxidase-mediated ROS pro-
duction in diabetic vessels is at least partially mediated
by protein kinase C (PKC) and NF-B [30,31]. Because
nicorandil exerts inhibitory effects on PKC activity [32]
and NF-B activation [33], nicorandil might prevent the
NADPH oxidase increase in diabetic rats by inhibiting
PKC or NF-B. Moreover, it has been suggested that
mitochondrial ROS may activate vascular NADPH oxi-
dase through a PKC-dependent process [34]. Eguchi et
al suggested that nicorandil inhibits ROS-induced ROS
release in the mitochondria of endothelial cells [35].
Therefore, nicorandil may inhibit NADPH oxidase by
protecting mitochondria.
Contribution of eNOS to ROS production in diabetes
eNOS can produce NO or superoxide. In oxidative
states, reduction in BH4, an essential cofactor of NOS,
results in uncoupling of eNOS [8], resulting in produc-
tion of superoxide by the eNOS monomer whereas the
d i m e r ,i nt h ep r e s e n c eo fa b u n d a n tB H 4, produces
mainly NO [14]. In the diabetic state, eNOS is believed
to serve as another source of ROS [25,36]; high glucose
can induce an eNOS uncoupling state due to BH4 defi-
ciency [6], leading to reduced NO production and
increased superoxide production [25,37]. In fact, there
are clinical and experimental reports describing adminis-
tration of BH4 as ameliorating endothelial dysfunction
[38,39]. In the present study, the expression of GCH-1,
a major enzyme for BH4 synthesis, was decreased in
STZ rats (Figure 3D), which was compatible with the
decrease in eNOS dimer/monomer ratio (Figure 3C).
These results suggest that ROS production in STZ rats
could be derived from un-coupled state of eNOS. In
fact, high glucose-induced ROS production in HCAECs
was completely inhibited by the NOS inhibitor L-NAME
(Figure 4D), suggesting that ROS production in STZ
rats could mainly be derived from eNOS.
Nicorandil was known to increase the eNOS expres-
sion and eNOS activity in several studies; not only in
normal rat hearts [40] but in several disease models
such as salt-sensitive Dahl rats [41,42], myocardial
infarcted rats [43] and monocrotaline-induced pulmon-
ary hypertensive rats [44], nicorandil increased eNOS
expression, which was inhibited by glybenclamide [40].
Increased NO release by nicorandil was correlated with
enhancement of eNOS phosphorylation in cultured rat
cardiac fibroblasts [45]. These increases in eNOS
expression were related to the improvement of symp-
toms. On the other hand, the present study demon-
strated that nicorandil decreased the increased
expression of total eNOS in STZ rats (Figure 3B) with
improvement of endothelial function. To our knowledge,
this is the first demonstration that nicorandil inhibits
the increased expression of eNOS in STZ-induced dia-
betic rats. There is a possibility about the mechanism of
inhibition of eNOS expression by nicorandil. In diabetes
rats, hyperglycemia increased superoxide production
through activation of the mitochondrial electron trans-
port chain [46], which activated PKC, resulting in eNOS
upregulation in endothelium [4,25]. Because nicorandil
and diazoxide have been known to reduce the mito-
chondrial ROS production [47], the reduction of the
mitochondrial ROS production by nicorandil may be
responsible for the inhibition of increased expression of
eNOS in STZ rats. Further investigation is required to
Figure 5 Effect of nicorandil on ROS production induced by
high-glucose treatment in HCAECs. HCAECs were exposed to high
glucose (35.6 mM) for 24 h, and nicorandil (100 μM) for the same
period. Representative images show DCF fluorescence in control (A),
high-glucose treatment (B) and high-glucose + nicorandil (C). High-
glucose treatment increased ROS production, which was prevented
by nicorandil (D). *p < 0.05 vs control, #p < 0.05 vs high-glucose (20
cells/dish from 3 dishes). Scale bar = 100 μm.
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lates eNOS expression.
Action mode of nicorandil
Since nicorandil is known to have KATP channel opening
effect and nitrate like activity, it is of interest which
action contributed to the endothelial protection in this
study. Earlier reports indicate the importance of KATP
channel in the endothelial protection by nicorandil;
nicorandil but not isosorbide dinitrate (ISDN) improved
FMD in the patients with ischemic heart disease [16].
We previously reported that nicorandil and diazoxide
but not ISDN improved FMD in paclitaxel-treated rats
[48]. These results suggest the importance of KATP
channel in the endothelial protection by nicorandil
although we could not rule out the contribution of
nitrate like activity. Further investigation will be
required to clarify the action mode of nicorandil on dia-
betes-induced endothelial dysfunction.
Protective effect of tempol from endothelial dysfunction
Tempol, a cell permeable superoxide dismutase mimetic,
protects animals and mammalian cells from cytotoxicity
induced by oxygen-free radicals like hydroxyl radicals,
H2O2,a n dO 2
- [49]. An additional property of tempol as
antioxidant is that it can penetrate cell membranes, and
hence react with both intracellular and extracellular oxy-
gen-free radicals. These properties make tempol attractive
for treatment of cardiovascular disease associated with oxi-
dative stress (e.g. diabetes, hypertension) [50]. In fact, tem-
pol can restore endothelium-dependent relaxation in
isolated small artery from rats with type I and type II dia-
betes through the reduction the levels of reactive oxygen
species [51]. In the present study, chronic administration
of tempol inhibited the endothelial dysfunction. Recently,
much higher dose of tempol (100 mg/kg/day in drinking
water, 12 days) than that in the present study has no effect
on the body weight, blood glucose and blood pressure in
STZ rat [52], although same higher dose of tempol has
hypotensive effects in hypertensive rats [50]. Taken
together, the present result suggests that tempol, as well as
nicorandil, may be another candidate for treatment of dia-
betic endothelial dysfunction.
Usefulness of FMD measurement in rats
Herein, we clearly observed reduced FMD in STZ rats
without changes in NTG-induced endothelium indepen-
dent relaxation (Figure 1). These results are consistent
with those in earlier reports showing that acetylcholine-
induced relaxation was diminished without affecting
endothelium-independent relaxation in isolated vascular
beds from STZ rats [27,38,53]. These results raise the pos-
sibility that FMD measurement will be a useful method
for investigating endothelial dysfunction in diabetic rats.
We consider evaluation of endothelial function by
measuring FMD in live rats to have at least 3 potential
advantages. First, FMD measurement can evaluate
endothelial function under both physiological and
pathological conditions. In the diabetic state, plasma
levels of humoral factors, autonomic nervous activity
and regional blood flow are altered. Hyperglycaemia
increases the levels of ROS [54], oxidative LDL [55] and
endothelin [56], thereby impairing endothelial function
in diabetic rats. These lines of evidence indicate that
results from isolated arterial strips may underestimate
the precise in vivo situation of endothelial dysfunction
because these humoral factors are absent from experi-
ments on isolated tissues. Second, we consider rats to
be more useful than large animals in many situations,
although FMD measurement can be applied not only for
clinical diagnosis but also experiments in large animals
such as dogs [57] and pigs [58]. We can conduct rat
experiments using small amounts of drugs, due to the
animal’s low body weight. Furthermore, many rat dis-
ease models are available. Finally, FMD makes it possi-
ble to repeatedly measure endothelial function in
individual rats. Time-dependent changes in pathological
conditions or chronic effects of drugs on endothelial
function can be traced in the same rat by permanent
implantation of an iliac artery occluder. Therefore, in
addition to the classical endothelial function measure-
ment method in isolated arteries, measurement of FMD
in living rats should also provide useful information for
not only elucidating endothelial physiology and pathol-
ogy but also ascertaining the roles of endothelial protec-
tive agents.
Clinical significance
In diabetic patients, morbidity and mortality rise due to
diabetic vascular complications such as atherosclerosis,
retinopathy and nephropathy, triggered by endothelial
dysfunction. Glycaemic control agents, statins and
renin-angiotensin system inhibitors ameliorate endothe-
lial dysfunction [59], thereby improving prognosis. In
this study of diabetic rats, nicorandil protected against
endothelial dysfunction through inhibition of ROS pro-
duction without glycaemic control. This result may sug-
gest that nicorandil can improve the prognosis of
patients with ischemic heart disease and diabetic com-
plications through not only the pharmacological precon-
ditioning effect, but also an endothelial protective effect.
In fact, the IONA [60] and J-CAD [61] studies demon-
strated nicorandil to improve the prognosis of patients
with ischemic heart disease and diabetes.
Conclusions
The present study demonstrated that nicorandil amelio-
rated endothelial dysfunction in STZ rats through an
Serizawa et al. Cardiovascular Diabetology 2011, 10:105
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phox and
eNOS uncoupling.
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